03 June 2026
03 June 2026
The Google Ventures-backed company could become the first to commercialise a reversible male contraceptive drug, provided the gel is successful in Phase III.
Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise.
The decision is supported by results from the Phase III ECLIPSE study, which assessed Aquipta versus placebo for migraine.
While Summit’s Harmoni-6 results drew a mixed reaction, Eli Lilly’s positive Retvemo data was expanded its potential in adjuvant NSCLC.
Smart pharma is becoming reality. At PHARMAP 2026, industry leaders discussed the technologies transforming pharmaceutical production, supply-chain security and global healthcare delivery.
Readouts in rare blood cancers like myelofibrosis, WM and CLL are attracting keen interest at this year’s ASCO conference.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
